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The COVID-19 pandemic and related socioeconomic events have markedly changed the 
environment in which cancer clinical trials are conducted.  These events have resulted in a 
substantial, immediate-term decrease in accrual to both diagnostic and therapeutic cancer 
investigations as well as substantive alterations in patterns of oncologic care.  The sponsors of 
clinical trials, including the United States National Cancer Institute, as well as the cancer centers 
and community oncology practices that conduct such studies, have all markedly adapted their 
models of care, usage of health care personnel, and regulatory requirements in the attempt to 
continue clinical cancer investigations while maintaining high levels of patient safety.  In doing 
so, major changes in clinical trials practice have been embraced nationwide.  There is a growing 
consensus that the regulatory and clinical research process alterations that have been adopted in 
response to the pandemic (such as the use of telemedicine visits to reduce patient travel 
requirements and the application of remote informed consent procedures) should be implemented 
long term.  The COVID-19 outbreak has also refocused the oncologic clinical trials community 
on the need to bring clinical trials closer to patients by dramatically enhancing clinical trial 
access, especially for minority and underserved communities that have been disproportionately 
affected by the pandemic.  In this Commentary, changes to the program of clinical trials 
supported by the National Cancer Institute that could improve clinical trial availability, 
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Better understanding of cancer biology, new forms of targeted therapies, and the 
explosion of immuno-oncology has resulted in an unprecedented expansion of United States 
Food and Drug Administration (FDA)-approved therapeutic options for cancer patients as well as 
an increase in life expectancy (1).  At the heart of this progress have been clinical trials 
supported by the National Cancer Institute (NCI), industry, and cancer centers across the 
country.  However, even before devastating recent political, economic, and health-related events 
unfolded, the extensive resources required to support the current clinical cancer research 
enterprise have deeply stressed the capacity of both community oncology practices and academic 
sites to carry out their research missions, especially in underserved populations (2-4).  Hence, at 
the conclusion of this commentary, we wish to suggest a series of changes to the NCI’s clinical 
trials programs that could markedly enhance their availability, operational efficiency, and 
implementation across a much wider segment of the populace.  
The deleterious effect of the COVID-19 pandemic on the American health care system 
has been substantial.  Oncologists have appropriately de-prioritized non-emergent clinical cancer 
care and non-COVID-19-related translational research.  The responsibilities of many clinical and 
cancer research staff have been shifted from investigational programs to assist in studies of 
COVID-19-associated medical interventions.  For these reasons, access to cancer clinical trials as 
well as to many standard-of-care treatments has plummeted over the past months, particularly at 
academic medical centers and community sites located in those geographic regions hardest hit by 
the pandemic (5,6).  If current trends continue, clinical trial accrual for NCI-funded studies alone 
will decrease by approximately 20-25% (or ~3,500 patients) in 2020 (7).  By default, decreased 
accrual will prolong the time needed to determine whether new treatments and other 
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development.  These delays will adversely affect the rate of progress resulting from recent 
advances in cancer research and most likely diminish the rapid pace of FDA approvals of new 
cancer therapies observed before COVID-19.  Decreased accrual will also delay clinical research 
efforts designed to reduce cancer incidence rates and to ameliorate acute and long-term sequelae 
of cancer treatments (8,9). 
Furthermore, the rising cost of treatment for cancer patients is not sustainable, 
particularly in the context of the enormous economic impact of the pandemic (10-12).  Patients 
must now weigh the potential for financial hardship that can accompany a diagnosis of cancer in 
the context of rising unemployment levels that are associated with loss of health insurance 
provided by employers (11).  These observations suggest that a renewed focus on prevention, 
detection, and cost-effective implementation and treatment is needed to assure that all patients 
benefit from advances in cancer care, especially patients in rural and underserved regions of the 
United States.          
The dramatic effects of the COVID-19 pandemic on the cancer research enterprise have 
coincided with the realization that the exponential growth in the complexity and expense 
associated with cancer clinical trials may threaten the vitality of the clinical trials endeavor.  
Hence, developing less expensive trials that are more convenient for patients and that demand 
meaningful clinical outcomes rather than simple statistical significance should become a clinical 
research imperative.  Adapting to current clinical realities by dramatically streamlining the 
clinical research paradigm in oncology is an urgent need.  We must modernize the process of 
clinical trial design and execution, decrease regulatory hurdles, and focus new studies on fewer 
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The impact of these trends is magnified in underserved populations that, before COVID-
19, had already experienced diminished access to state-of-the-art clinical trials (14).  COVID-19 
and cancer disproportionately produce adverse outcomes in African Americans, Hispanics, and 
Native Americans patients (15).  The Johns Hopkins University and American Community 
Survey found that the infection rate in 131 predominantly Black counties in the United States 
was over three-fold greater than in predominantly White counties.  At least some of these 
differences may be attributable to a higher incidence of pre-pandemic risk factors among Black 
patients, such as diabetes, obesity, hypertension, and cardiovascular disease, which are 
associated with reduced access to health care (16,17).   
Oncologists have long recognized the poorer health outcomes in African Americans 
compared to their White counterparts.  Death from all cancer types is 13% higher in Black 
patients compared to White patients (18).  Putative causes of these disparities include 
socioeconomic issues and decreased access to care; but at the core is a lack of attention to what 
Berwick and others call the moral determinants of health (19).  These determinants include an 
individual’s condition of birth, education, work environment, the social concerns of elders, 
community resilience, social and economic security, and the basic equity level in society.  Our 
current cancer clinical trial paradigm has also presented substantive obstacles to the inclusion of 
underserved populations, including African Americans.  By design, cancer clinical trials have 
developed rigid eligibility criteria and often include frequent and expensive “standard of care” 
tests and procedures, such as functional imaging examinations, that often exclude patients with 
multiple co-morbid conditions, transportation issues, and inadequate health insurance—including 
substantial co-pays (20,21).  Recent evidence from the NCI-supported clinical trials performed 
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industry versus NCI-sponsored investigations (22).  Finally, the emerging economic crisis 
resulting from the COVID-19 pandemic has further heightened socioeconomic disparities 
between white patients and patients of color.  Black patients are experiencing disproportionate 
loss of employment and health insurance, which may limit the feasibility of participating in 
complex trials requiring frequent health care visits and procedures (23).  
In the last several months, regulatory agencies and clinical trial sponsors (including the 
NCI) have demonstrated the ability to adapt rapidly to the exigencies imposed by the infection of 
a proportion of the US population with SARS-CoV-2 (24,25).  These changes have included: 
broad acceptance of electronic informed consent, transfer of the clinical care of trial patients to 
local providers to diminish travel requirements, shipping of oral investigational agents to local 
sites, decreasing the impact of minimal protocol deviations on the assessment of clinical trial site 
performance, remote auditing of clinical trial documents, and, perhaps most importantly, 
accepting the validity of clinical trial assessments performed using telehealth approaches.  All 
these adaptations to minimize disruptions to ongoing clinical studies and to maximize access to 
clinical trials during the COVID-19 pandemic demonstrate clearly that major changes to the 
currently accepted standards for the conduct of cancer clinical investigations are feasible.  And 
that the time horizon to implement such changes need not be excessive. 
In the context of the current health care milieu, which is likely to continue for the 
foreseeable future, there is an urgent need to adapt our clinical research enterprise to a “new 
normal”.  This “new normal” must facilitate simpler, faster, flexible, and less expensive trials 
that seamlessly integrate with the needs of daily clinical practice.  It is imperative that we begin 
testing new approaches to address essential modifications of our clinical trials system.  Taking 
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verbal informed consents, allowances for diminished travel to cancer centers for diagnostics and 
treatments), additional novel strategies to improve the efficiency of clinical cancer research 
should be promulgated.  
 
Clinical Trial Initiatives 
We propose that the current environment demands consideration of a series of initiatives 
throughout NCI-supported clinical trials networks, and hopefully elsewhere, that will address 
impediments to rapid clinical trial execution.  These initiatives include the following:    
 
Enhancing patient access 
Cancer clinical trials must be brought to the patient—rather than the converse--without regard to 
geography.  Additional local clinical trial sites should be developed at affordable costs that 
utilize advances in telemedicine pioneered during the COVID-19 pandemic.  This has major 
implications for patients with rare malignancies as well as for underserved populations and the 
institutions that serve them.  This effort, building on the recent activities of Friends of Cancer 
Research, ASCO and others (26), should include designing trials that permit entry of patients 
with a wide variety of chronic comorbidities, thus broadening the range of patients eligible for 
clinical study.  It should also include developing studies conducive to implementation in safety-
net hospitals.  In part, this will involve adequately supporting and training clinical research teams 
that now lack the necessary infrastructure needed to enroll underserved patient populations in 
cancer clinical investigations.  
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Electronic data collection methods should be developed that are fully compatible with remote 
auditing and trial monitoring by way of electronic health records (EHRs).  These methods must 
complement current electronic data entry techniques, minimize in-person visits to distant clinical 
trials sites, and promote more uniform and robust data collection.  This effort should be coupled 
with a program to ease the administrative burden and cost of repeatedly creating custom local 
versions of study records and forms compatible with local EHRs and clinical trial monitoring 
systems.  We do not suggest generating so-called ‘shadow charts’ for patients enrolled on 
clinical studies.  Rather, working with the major EHR vendors, the NCI should support a national 
effort at its clinical trial sites to harmonize the electronic representation of clinical data in a 
fashion that will facilitate simpler, automated cross validation and usage of standardized 
electronic order sets, auditing, and data entry for its clinical investigations at all centers.  
 
Transforming statistical designs 
Clinical trial design should strive to provide meaningful endpoints that require less data 
acquisition.  We need to test new trial formats that simplify data management compared with 
current NCTN, ETCTN, or NCORP standards—to answer the question of whether the current 
approach is actually needed to change clinical practice or to meet regulatory endpoints.  One 
example is to investigate and compare whether electronically collected patient-reported 
outcomes or simpler time to event endpoints could reduce the need for more frequent imaging 
studies while still providing reliable information sufficient to support the results of cancer 
clinical trials.     
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It will be important to create more innovative processes to enable rapid evaluation of clinical 
trial documents, such as letters of intent, protocols, and protocol amendments.  This is especially 
true for the evaluation and approval of trials for rare tumors that would not typically be opened at 
non-academic sites because of the allocation of resources for higher incidence malignancies.   
 
Rethinking strategic research infrastructure 
The personnel requirements for the review, activation, and monitoring of clinical trials have 
expanded dramatically.  Tools and processes should be developed to substantively diminish the 
person-hours required for study development and conduct (including the development of 
electronic rather than in-person protocol auditing) to decrease time to trial completion. 
 
Simplifying the regulatory framework 
In concert with FDA, regulatory obligations for cancer clinical trials need to be simplified 
without jeopardizing patient safety.  This includes re-evaluating mandatory requirements for 
reporting certain data elements, such as minor protocol deviations and low-grade adverse events.  
We need a much better understanding of the impact of different reporting thresholds for an array 
of data elements on meeting pre-defined clinical research and safety endpoints. 
 
Minimizing non-essential tests 
We need to more rigidly identify essential and non-essential testing on clinical trials.  Many 
extraneous “standard-of-care” tests are included in trials because of the possibility that they may 
be needed for registration of a drug by the FDA.  This leads to excessive trial costs, including 
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Promoting the use of electronic consent 
In accordance with the 2016 FDA guidance to reduce paperwork, we should provide improved 
flexibility to allow for an informed consent process that can be conducted remotely.    
 
Conclusions 
At the crossroads of cancer, COVID-19, and growing social inequities, substantive 
opportunities to improve the current methodology of oncologic clinical investigation have 
manifested themselves in dramatic fashion.  Now is the time to make fundamental changes that 
will lead to sustainable improvements in our approach to and conduct of clinical cancer research, 
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